Triomics raises $22 million to scale oncology AI platform

Triomics, a startup building an artificial intelligence platform for oncology—the medical field focused on cancer—has raised $22 million in a Series B funding round. A Series B round represents a company’s second major round of venture capital financing. The funding round was led by Battery Ventures, with participation from several returning backers:

• Nexus Venture Partners
• Lightspeed
• Y Combinator

The startup addresses administrative challenges in cancer care, where medical breakthroughs keep patients alive longer but generate dense, multi-year medical records. A typical medical chart includes physician progress notes, imaging and pathology reports, and scans of faxes, making review times lengthy. In this complex medical environment, staff burnout is a persistent problem. “We have seen medical records [with] thousands of pages of information,” said Triomics co-founder and CEO Sarim Khan, who started the company in 2021 alongside co-founder and CTO Hrituraj Singh.

To manage this administrative load, Triomics helps healthcare institutions automate tasks such as clinical trial matching and tumor report submissions, which are a legal mandate for cancer centers. Initially focused on helping doctors identify clinical trials, the company expanded its platform to add verifiable patient summaries as part of a broader visit-preparation workflow. These summaries surface key information directly within the tools clinicians already use, without requiring them to switch applications, which reduces appointment preparation time and gives oncologists more time with patients. According to Khan, Triomics has expanded its enterprise customer base fourfold over the past year, driving a tenfold increase in annualized recurring revenue. The platform is currently used by institutions including Memorial Sloan Kettering and Yale Cancer Center. The startup previously raised a $15 million Series A funding round in mid-2024.

Triomics operates in a competitive market alongside AI medical scribes such as Abridge and Microsoft’s Nuance, which use AI to listen to and document patient-doctor conversations. However, Triomics differentiates its platform by training its models specifically on oncology data, rather than relying on generic AI agents to summarize patient charts.

Why it matters

Triomics is scaling its oncology-specific AI platform to automate administrative burdens like clinical trial matching, addressing the critical issue of clinician burnout in complex medical environments.